Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

TMDXBullishAnalyst Target Updateanalyst

Medium materiality6/10

Canaccord Raises TransMedics Price Target to $120

Nov 7, 2026, 12:08 AM EST1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The target revision is bullish, although the post-signal rise means some of the move may already have occurred; analyst targets are opinions, not forecasts.

AI summary

What happened, with direct paths to the underlying reporting

Canaccord raised its TMDX target to $120 versus a posted price of $68.98. The stock had already risen 27.92% since the signal, but the target remains materially higher.

Canaccord raised its TMDX target to $120; price was $68.98 at posting.
TMDX was up 27.92% since the signal.

Key facts

01
Target: $120
02
Posted price: $68.98
03
Analyst firm: Canaccord Genuity
04
Analyst: Jason Mills

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.